Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291601 · ClinicalTrials.gov registry record · Phase 3
Preoperative CHG Cloth on Healthy Subjects
A Phase 3 study, sponsored by Medline Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 879
- Enrollment target
NCT02291601: Completed Phase 3 study, sponsored by Medline Industries.
NCT02291601 is a Phase 3 study that has completed, run by Medline Industries. The registered enrollment target is 879 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02291601, a Phase 3 study, has completed, sponsored by Medline Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 879 participants
- Enrollment target
Study Summary
Evaluate the effects of CHG cloth on the reduction of bacteria on the skin.
Primary Outcome
Percent of abdomen and groin sites that achieve a 2-Log or 3-Log reduction respectively of bacterial flora from baseline. Note: The number of participants in each treatment group (abdomen and/or groin) can vary depending on whether participants achieved qualifying microbial levels on the abdomen and groin at baseline.
Interventions
- OTHER Vehicle
- DRUG Chlorhexidine Gluconate
- DRUG DynaHex-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 879 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
What the finished NCT02291601 record still lists
NCT02291601 is an interventional study that assigns participants to a tested intervention. The registered 879 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT02291601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02291601 about?
NCT02291601 is a clinical study titled "Preoperative CHG Cloth on Healthy Subjects". Evaluate the effects of CHG cloth on the reduction of bacteria on the skin.
What is the current status of trial NCT02291601?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 879 participants. The study started on 2014-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02291601?
The interventions under investigation include: Vehicle (OTHER), Chlorhexidine Gluconate (DRUG), DynaHex-2 (DRUG).
Who is sponsoring clinical trial NCT02291601?
This trial is sponsored by Medline Industries, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02291601's enrollment target sits among peer trials
879 370th of 2000 higher than 1,631 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia